Rafferty Asset Management
ANIP icon

Rafferty Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Rafferty Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,851
Closed -$225K – 1064
2025
Q4 		$225K Buy
2,851
+632
+28% +$54.7K ﹤0.01% 1068
2025
Q3 		$203K Buy
+2,219
New +$181K ﹤0.01% 1071
2025
Q1 		– Sell
-3,622
Closed -$200K – 1064
2024
Q4 		$200K Buy
+3,622
New +$208K ﹤0.01% 1107
2019
Q3 		– Sell
-10,614
Closed -$872K – 803
2019
Q2 		$872K Buy
+10,614
New +$755K 0.02% 584

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rafferty Asset Management's ANIP Position: Q1 2026 in Review

Rafferty Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 2,851 shares — an estimated $225K sold.

Rafferty Asset Management first reported a position in ANIP in Q2 2019 and held it in 4 quarters. The position peaked at $872K in Q2 2019. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Rafferty Asset Management reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 2,851 ANI Pharmaceuticals shares in Q1 2026, an estimated $225K.
  • Rafferty Asset Management first reported a position in ANI Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • Rafferty Asset Management's ANI Pharmaceuticals position peaked at $872K in Q2 2019.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.